The inhibition of the TGF-β/Smad signal pathway has shown promise in ameliorating fibrosis, and it may represent a potential therapeutic target for pulmonary fibrosis treatment [116,117]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.